Alumis

aid: alumis
name: Alumis
description: 'Alumis Inc. (NASDAQ: ALMS) is a clinical-stage biopharmaceutical company headquartered at 280 East Grand Avenue,
  South San Francisco, California, developing oral therapies for immune-mediated diseases. Incorporated in 2021 as Esker Therapeutics
  and renamed Alumis in January 2022, its pipeline is led by envudeucitinib, an oral allosteric TYK2 inhibitor in Phase 3
  for moderate-to-severe plaque psoriasis and systemic lupus erythematosus; A-005, a CNS-penetrant TYK2 inhibitor for neuroinflammatory
  and neurodegenerative disease; and lonigutamab, a subcutaneously delivered anti-IGF-1R antibody for thyroid eye disease.
  Alumis describes a proprietary precision data-analytics platform that integrates genetic, genomic, proteomic, biological
  and clinical insight, but it is an internal therapeutic-development capability and is not exposed publicly. The company
  publishes no developer portal, API documentation, SDKs or machine-readable specifications.'
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://www.alumis.com/themes/default/images/logo.svg
url: https://raw.githubusercontent.com/api-evangelist/alumis/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Healthcare
- Immunology
- Drug Development
- Clinical Trials
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/alumis-domain-security.yml
- type: Website
  url: https://www.alumis.com/
- type: About
  url: https://www.alumis.com/about/
- type: Careers
  url: https://www.alumis.com/careers/
- type: PrivacyPolicy
  url: https://www.alumis.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/alumis-co/
- type: Twitter
  url: https://twitter.com/_Alumis
- type: InvestorRelations
  url: https://investors.alumis.com/
- type: SecondaryMarket
  url: https://forgeglobal.com/alumis_stock/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Alumis is a clinical-stage biopharmaceutical company whose product is oral TYK2/IGF-1R drug candidates, not software;
    its site has only about/science/pipeline/patients/careers sections and every developer-shaped path (/developers, /api,
    /docs, /openapi.json, /graphql, /llms.txt, /.well-known/*) returns a hard 404, and the only "alumis" GitHub org is an
    unrelated Scandinavian TypeScript/C# shop.
  evidence:
  - url: https://www.alumis.com/developers
    status: 404
  - url: https://www.alumis.com/openapi.json
    status: 404
  - url: https://www.alumis.com/.well-known/agent-card.json
    status: 404
  - url: https://www.alumis.com/llms.txt
    status: 404
  - url: https://www.alumis.com/
    status: 200
  checked: '2026-08-06'